183P Clinical treatment score post-5 years (CTS5) as a tool for risk estimation of late recurrence in Thai patients with estrogen receptor positive, early breast cancer: A validation study

Abstract

The rate of late distant recurrence of hormonal receptor (HR) positive breast cancer continued steadily even after 5 years of endocrine treatment. Clinical Treatment Score post-5 years (CTS5) was developed and validated as a tool to assess the risk of late distant relapse (LDR) using data from ATAC and BIG1-98. This study aimed to externally validate CTS5 in a real-world cohort of HR positive breast cancer patients diagnosed and treated at an academic center in Thailand.